Harmony Biosciences (HRMY) News Today → 4 Cryptos BETTER than Bitcoin (From True Market Insiders) (Ad) Free HRMY Stock Alerts $29.03 -0.28 (-0.96%) (As of 05/17/2024 08:53 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 1:56 AM | americanbankingnews.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 17 at 1:53 AM | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Consensus Rating of "Moderate Buy" from AnalystsHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and six haveMay 10, 2024 | marketbeat.comLSV Asset Management Acquires Shares of 75,053 Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)LSV Asset Management bought a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 75,053 shares of the company's stock, vaMay 6, 2024 | msn.comHarmony Biosciences Expands into Rare Epilepsy Market with Epygenix Therapeutics AcquisitionMay 4, 2024 | finance.yahoo.comResults: Harmony Biosciences Holdings, Inc. Beat Earnings Expectations And Analysts Now Have New ForecastsMay 3, 2024 | finance.yahoo.comHarmony Biosciences Holdings First Quarter 2024 Earnings: EPS Beats ExpectationsMay 2, 2024 | markets.businessinsider.comLooking for a Growth Stock? 3 Reasons Why Harmony Biosciences is a Solid ChoiceMay 2, 2024 | msn.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call TranscriptMay 1, 2024 | finance.yahoo.comHarmony Biosciences Holdings Inc (HRMY) Q1 2024 Earnings Call Transcript Highlights: Strong ...May 1, 2024 | msn.comEasterly Government Properties, Inc. (NYSE:DEA) Q1 2024 Earnings Call TranscriptMay 1, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Releases Earnings Results, Beats Expectations By $0.07 EPSHarmony Biosciences (NASDAQ:HRMY - Get Free Report) released its quarterly earnings results on Tuesday. The company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.07. Harmony Biosciences had a return on equity of 27.49% and a net margin of 22.16%. The company had revenue of $154.62 million for the quarter, compared to analysts' expectations of $154.10 million. During the same period in the prior year, the firm earned $0.48 earnings per share. The firm's revenue was up 29.8% compared to the same quarter last year.April 30, 2024 | msn.comRapidly Growing Harmony Biosciences Sees 30% Increase in Net Revenue, Boosts Growth Strategy With Rare Epilepsy Franchise AcquisitionApril 30, 2024 | bizjournals.comHarmony Biosciences shares soar on acquisition of New Jersey epilepsy drug developerApril 30, 2024 | fool.comHarmony Biosciences (HRMY) Q1 2024 Earnings Call TranscriptApril 30, 2024 | marketbeat.comJackson Creek Investment Advisors LLC Takes $991,000 Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Jackson Creek Investment Advisors LLC purchased a new stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 30,683 shares of the company's stock, valuApril 30, 2024 | seekingalpha.comHarmony Biosciences: Company's Q1 Update Music To Investor Ears (Upgrade)April 30, 2024 | marketwatch.comHarmony Biosciences Buys Epygenix Therapeutics For Initial $35 MillionApril 30, 2024 | marketwatch.comHarmony Biosciences Shares Rise After Earnings, AcquisitionApril 30, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY), Moderna (MRNA) and Ionis Pharmaceuticals (IONS)April 30, 2024 | markets.businessinsider.comKey Takeaways From Harmony Biosciences Analyst RatingsApril 30, 2024 | msn.comHRMY Stock Earnings: Harmony Biosciences Beats EPS, Misses Revenue for Q1 2024April 30, 2024 | finance.yahoo.comHarmony Biosciences Exceeds Analyst Revenue Forecasts While Aligning with EPS Projections in Q1 2024April 30, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $29.25Harmony Biosciences (NASDAQ:HRMY) Shares Gap Up to $29.25April 30, 2024 | seekingalpha.comHarmony Biosciences Holdings, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 30, 2024 | marketbeat.comHarmony Biosciences' (HRMY) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and issued a $50.00 target price on shares of Harmony Biosciences in a report on Tuesday.April 30, 2024 | globenewswire.comHarmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare EpilepsyApril 30, 2024 | prnewswire.comHarmony Biosciences Acquires Epygenix Therapeutics, Inc., Adding Late-Stage Epilepsy Franchise to Growing Pipeline of Innovative CNS AssetsApril 29, 2024 | markets.businessinsider.comHarmony Biosciences earnings: here's what Wall Street expectsApril 29, 2024 | msn.comHarmony Biosciences Q1 2024 Earnings PreviewApril 28, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Paradiem LLCParadiem LLC boosted its stake in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 38.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,031 shares of the company's stock aApril 25, 2024 | marketbeat.comabrdn plc Sells 48,455 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)abrdn plc reduced its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 8.3% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 533,189 shares of the company's stock after selling 48,455 shares during the period. abrdn plc owneApril 23, 2024 | marketbeat.comHarmony Biosciences (HRMY) Set to Announce Quarterly Earnings on TuesdayHarmony Biosciences (NASDAQ:HRMY) will be releasing earnings before the market opens on Tuesday, April 30, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=585034)April 23, 2024 | marketbeat.comHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Position Boosted by Federated Hermes Inc.Federated Hermes Inc. boosted its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 2,132.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 525,337 shares of the company's stocApril 22, 2024 | msn.comHarmony Biosciences to Unveil Q1 2024 Financial ResultsApril 16, 2024 | marketbeat.comHealthInvest Partners AB Takes $4.68 Million Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)HealthInvest Partners AB purchased a new stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 145,000 shares of the company's stock, valued atApril 16, 2024 | finance.yahoo.comHARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024April 15, 2024 | msn.comHarmony Biosciences Secures Exclusive Rights to Promising Narcolepsy TreatmentApril 12, 2024 | investing.comHarmony Biosciences secures rights to narcolepsy treatmentApril 12, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Stock Rating Reaffirmed by Cantor FitzgeraldCantor Fitzgerald restated an "overweight" rating and set a $49.00 target price on shares of Harmony Biosciences in a research note on Friday.April 11, 2024 | msn.comHarmony inks licensing deal for sleep disorder therapyApril 11, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Stock Price Up 4.7%Harmony Biosciences (NASDAQ:HRMY) Trading Up 4.7%April 11, 2024 | finance.yahoo.comHARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONISTApril 11, 2024 | prnewswire.comHARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONISTApril 9, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research report on Tuesday.April 8, 2024 | msn.comHarmony Biosciences Launches Phase 3 Trial for Potential Prader-Willi Syndrome TreatmentApril 8, 2024 | marketbeat.comHarmony Biosciences (NASDAQ:HRMY) Sees Unusually-High Trading VolumeHarmony Biosciences (NASDAQ:HRMY) Sees Large Volume IncreaseApril 4, 2024 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)Vanguard Group Inc. grew its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 2.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,684,152 shares of the company's stock after acquiring an adApril 3, 2024 | finance.yahoo.comHARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROMEApril 1, 2024 | msn.comHarmony Biosciences to Spotlight Innovations at Needham Virtual Healthcare ConferenceMarch 28, 2024 | markets.businessinsider.comEvaluating Harmony Biosciences: Insights From 8 Financial Analysts Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Next President (Not Trump. Not Biden.) (Ad)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump. Click here to see why it will be ______ _________. HRMY Media Mentions By Week HRMY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HRMY News Sentiment▼1.120.42▲Average Medical News Sentiment HRMY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HRMY Articles This Week▼24▲HRMY Articles Average Week Get Harmony Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Schrödinger News Structure Therapeutics News Protagonist Therapeutics News Edgewise Therapeutics News Kura Oncology News Supernus Pharmaceuticals News Taro Pharmaceutical Industries News Spyre Therapeutics News Ardelyx News Arcus Biosciences News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HRMY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward Press"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersMost important medical advance in 100 yearsThe Oxford Club Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
